Literature DB >> 31828327

Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.

Virginia A Triant1,2,3,4, Mark J Siedner1,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31828327      PMCID： PMC6996858          DOI： 10.1093/infdis/jiz482

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  18 in total

1.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

2.  Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Authors:  Lene Ryom; Jens D Lundgren; Wafaa El-Sadr; Peter Reiss; Ole Kirk; Matthew Law; Andrew Phillips; Rainer Weber; Eric Fontas; Antonella d' Arminio Monforte; Stéphane De Wit; Francois Dabis; Camilla I Hatleberg; Caroline Sabin; Amanda Mocroft
Journal:  Lancet HIV       Date:  2018-05-03       Impact factor: 12.767

Review 3.  Contemporary protease inhibitors and cardiovascular risk.

Authors:  Jens Lundgren; Amanda Mocroft; Lene Ryom
Journal:  Curr Opin Infect Dis       Date:  2018-02       Impact factor: 4.915

4.  Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.

Authors:  Antonella d'Arminio Monforte; Peter Reiss; Lene Ryom; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Signe W Worm; Mathew G Law; Rainer Weber; Ole Kirk; Christian Pradier; Andrew N Phillips; Jens D Lundgren; Caroline A Sabin
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

5.  Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.

Authors:  Paolo Maggi; Chiara Bellacosa; Armando Leone; Anna Volpe; Elena Delfina Ricci; Nicoletta Ladisa; Stefania Cicalini; Elisabetta Grilli; Rosaria Viglietti; Antonio Chirianni; Lara Ines Bellazzi; Renato Maserati; Canio Martinelli; Paola Corsi; Benedetto Maurizio Celesia; Federica Sozio; Gioacchino Angarano
Journal:  Atherosclerosis       Date:  2017-05-05       Impact factor: 5.162

6.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

7.  Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

Authors:  Murielle Mary-Krause; Laurent Cotte; Anne Simon; Maria Partisani; Dominique Costagliola
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

8.  Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.

Authors:  A González-Cordón; M Doménech; M Camafort; M Martínez-Rebollar; B Torres; M Laguno; J Rojas; M Loncà; J L Blanco; J Mallolas; J M Gatell; E de Lazzari; E Martínez
Journal:  HIV Med       Date:  2018-05-10       Impact factor: 3.180

9.  Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.

Authors:  Joanne LaFleur; Adam P Bress; Lisa Rosenblatt; Jacob Crook; Paul E Sax; Joel Myers; Corey Ritchings
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

10.  Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.

Authors:  Anne Marie Kerchberger; Anandi N Sheth; Christine D Angert; C Christina Mehta; Nathan A Summers; Ighovwerha Ofotokun; Deborah Gustafson; Sheri D Weiser; Anjali Sharma; Adaora A Adimora; Audrey L French; Michael Augenbraun; Jennifer Cocohoba; Seble Kassaye; Hector Bolivar; Usha Govindarajulu; Deborah Konkle-Parker; Elizabeth T Golub; Cecile D Lahiri
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079
View more
  4 in total

Review 1.  Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.

Authors:  Caroline Joseph Kiriacos; Monika Rafik Khedr; Miray Tadros; Rana A Youness
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

Review 2.  Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application.

Authors:  Kamoru A Adedokun; Ayodeji O Olarinmoye; Lawal O Olayemi; Muhammed R Shehu; Jelili O Mustapha; Ramat T Kamorudeen; Sulaimon A Nassar
Journal:  J Clin Transl Res       Date:  2021-03-12

Review 3.  COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.

Authors:  Soha R Abd El Hadi; Esmat E Zien El-Deen; Mostafa M Bahaa; Abdelfattah A Sadakah; Heba A Yassin
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162

Review 4.  Drug repurposing approach to fight COVID-19.

Authors:  Thakur Uttam Singh; Subhashree Parida; Madhu Cholenahalli Lingaraju; Manickam Kesavan; Dinesh Kumar; Raj Kumar Singh
Journal:  Pharmacol Rep       Date:  2020-09-05       Impact factor: 3.919
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.